Iressa price issue: a signal for drug price slashing policy?

Published: 2006-08-10 06:58:00

Updated: 2006-08-10 06:58:00

The price down of Iressa, a lung cancer drug, is now on a hot dispute among the MOHW, the civil health/medical groups and AZ company where is claiming that its price reduction has lack of justification.

AZ won the administrative lawsuit for an interim injunction against the price slash, for wh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK